Encumbrance created on 57.49% shares via offshore loan facility

Pledge Above 50pctOwnership Changes View source PDF

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-2.4%1-day move

₹414.10

prior close

₹405.50

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.1+0.2+0.0-2.4+10.4+11.1+10.3+8.7+8.9+8.3+8.5——

Up moveDown movePending

AI summary

CSC Global Capital Markets, acting as agent for lenders (Barclays, Deutsche Bank, BNP Paribas, MUFG, Standard Chartered), disclosed creation of encumbrance over 21.99 crore shares (57.49%) of Cohance Lifesciences. Promoter entities Berhyanda (33.34%) and Jusmiral Holdings (24.15%) availed term loans under a Facility Agreement dated June 11, 2026, effective June 16, 2026. The pledge is indirect, via 100% shares of the Borrowers pledged by their shareholders, with restrictions on disposal of the Cohance shares.

Likely market impact

Majority promoter stake now encumbered via offshore loan covenants. Restricts share disposal and signals leverage taken by promoters. Monitor for default risk.